PredictImmune’s IBD Test Soon Will Be Available in US, Canada, Across French-speaking Europe

PredictImmune’s IBD Test Soon Will Be Available in US, Canada, Across French-speaking Europe
Following product launches in the United Kingdom (UK) and Ireland earlier this year, the developer of the first validated test for inflammatory bowel disease (IBD) now has reached commercialization agreements in the U.S. and Canada, and across French-speaking Europe. That developer, PredictImmune, is partnering exclusively in North America with KSL Biomedical (KSL) to bring to market the pioneering prognostic biomarker test PredictSURE IBD. The pact calls for KSL to commercialize the product and fulfill orders, and to receive and process samples through its molecular testing lab. PredictImmune called the agreement — marking its first launch outside the UK — a “significant milestone” in its quest to make the assay available globally. PredictSURE IBD is expected to be available in North America by the first quarter of next year. “PredictSURE IBD is a major step towards personalized medicine in IBD and we are delighted that, via  our partnership with KSL, patients across North America will now have access to this prognostic tool to enable informed treatment decisions to be made at the point of diagnosis,” Paul Kinnon, PredictImmune CEO, said in a press release. “This is an exciting test, serving unmet needs on several levels," said Long Shen, KSL’s chief scientific officer. "Gastroenterologists want the best assessment of prognosis to inform their choice of treatment and deliver patient benefits, driven by an improved understanding of the implications of diagnosis and more effective implementation of the best therapy. All while lowering the cost of treatment. It’s a win-win-win,” Shen said. KSL focuses on advancing genomic and proteomic translational medicine for therapeutic and diagnostic applications in immunology and oncology. Pre
Subscribe or to access all post and page content.